Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X5ZI
|
|||
| Former ID |
DAP001441
|
|||
| Drug Name |
Ambrisentan
|
|||
| Synonyms |
Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pulmonary arterial hypertension [ICD-11: BB01.0; ICD-9: 416] | Approved | [1], [2] | |
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H22N2O4
|
|||
| Canonical SMILES |
CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
|
|||
| InChI |
1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
|
|||
| InChIKey |
OUJTZYPIHDYQMC-LJQANCHMSA-N
|
|||
| CAS Number |
CAS 177036-94-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12015371, 14779987, 17194924, 43529863, 50551569, 51091419, 53787770, 57371956, 93309673, 103307060, 104035299, 114788055, 118855302, 126616865, 126651844, 131302629, 134338642, 135692418, 137237404, 139988399, 143497715, 144205520, 152133959, 152238501, 152258462, 160647297, 160826914, 162011508, 162172038, 163093066, 163387054, 164824132, 170465143, 174007223, 175267375, 175426501, 178100778, 179116973, 185986582, 187071933, 196107821, 198977886, 198991664, 204430246, 211534802, 223375980, 223532574, 223704800, 224518792, 226395806
|
|||
| ChEBI ID |
CHEBI:135949
|
|||
| ADReCS Drug ID | BADD_D00100 | |||
| SuperDrug ATC ID |
C02KX02
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin A receptor (EDNRA) | Target Info | Antagonist | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Endothelin signaling pathway | |||
| Pathway Interaction Database | Endothelins | |||
| EGFR-dependent Endothelin signaling events | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| Endothelin Pathways | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3951). | |||
| REF 2 | Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.